Literature DB >> 25116639

The four-year course of major depressive disorder: the role of staging and risk factor determination.

Lynn Boschloo1, Robert A Schoevers, Aartjan T F Beekman, Johannes H Smit, Albert M van Hemert, Brenda W J H Penninx.   

Abstract

BACKGROUND: Much is still unclear about the mechanisms underlying the course of major depressive disorder (MDD). This study aimed to identify risk factors that predict a poor prognosis of MDD while taking into consideration its chronicity at baseline.
METHODS: In patients with MDD (n = 767), we examined whether baseline clinical factors, sociodemographics, childhood trauma, personality and life events predicted the 4-year course (i.e., sustained recovery, temporary recovery and chronic course) of MDD. Baseline chronicity of MDD was taken into account by testing whether associations were different for patients with nonchronic versus chronic MDD at baseline.
RESULTS: In patients with nonchronic MDD at baseline, 27.8% developed a chronic disorder during follow-up, whereas 53.0% of patients with chronic MDD at baseline had a persistent chronic disorder during follow-up. Severity of MDD, childhood trauma and greater age were important general risk factors for a poor prognosis, independent of MDD chronicity at baseline. In contrast, low extraversion was only important for the course of nonchronic MDD at baseline, while higher education and negative life events (in patients with high neuroticism) were only relevant for the course of chronic MDD at baseline.
CONCLUSIONS: One out of 4 patients with nonchronic MDD progressed to a chronic disorder, while half of the patients with chronic MDD remained chronic during follow-up. Since several risk factors for a poor prognosis differed for patients with nonchronic and chronic MDD at baseline, treatment targets should be adjusted for current chronicity of MDD.

Entities:  

Mesh:

Year:  2014        PMID: 25116639     DOI: 10.1159/000362563

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  9 in total

1.  Multiple risk factors predict recurrence of major depressive disorder in women.

Authors:  Hanna M van Loo; Steven H Aggen; Charles O Gardner; Kenneth S Kendler
Journal:  J Affect Disord       Date:  2015-04-02       Impact factor: 4.839

2.  Exploring the Potential Antidepressant Mechanisms of Pinellia by Using the Network Pharmacology and Molecular Docking.

Authors:  Yu-Gang Xiao; Han-Biao Wu; Ji-Sheng Chen; Xiong Li; Zhi-Kun Qiu
Journal:  Metab Brain Dis       Date:  2022-03-01       Impact factor: 3.584

3.  Prognostic Value of Pathological Personality Traits for Treatment Outcome in Anxiety and Depressive Disorders: The Leiden Routine Outcome Monitoring Study.

Authors:  Wessel A van Eeden; Albert M van Hemert; Erik J Giltay; Philip Spinhoven; Edwin de Beurs; Ingrid V E Carlier
Journal:  J Nerv Ment Dis       Date:  2022-04-23       Impact factor: 1.899

4.  Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark.

Authors:  Sandra M Meier; Liselotte Petersen; Manuel Mattheisen; Ole Mors; Preben B Mortensen; Thomas M Laursen
Journal:  Lancet Psychiatry       Date:  2015-05-14       Impact factor: 27.083

Review 5.  A Review on the General Stability of Mood Disorder Diagnoses Along the Lifetime.

Authors:  Diego de la Vega; Ana Piña; Francisco J Peralta; Sam A Kelly; Lucas Giner
Journal:  Curr Psychiatry Rep       Date:  2018-04-02       Impact factor: 5.285

6.  Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China.

Authors:  Qian Zhou; Zhi-Guo Wu; Yun Wang; Xiao-Hua Liu; Jun Chen; Yong Wang; You-Song Su; Chen Zhang; Dai-Hui Peng; Wu Hong; Yi-Ru Fang
Journal:  CNS Neurosci Ther       Date:  2018-07-11       Impact factor: 5.243

7.  N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.

Authors:  Chenghao Yang; Fokko J Bosker; Jie Li; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2018-09-04       Impact factor: 3.630

8.  PRO*MDD Study Protocol: Effectiveness of Outpatient Treatment Programs for Major Depressive Disorder: Metacognitive Therapy vs. Behavioral Activation a Single-Center Randomized Clinical Trial.

Authors:  Anja Schaich; Laura Heikaus; Nele Assmann; Sandra Köhne; Kamila Jauch-Chara; Michael Hüppe; Adrian Wells; Ulrich Schweiger; Jan Philipp Klein; Eva Fassbinder
Journal:  Front Psychiatry       Date:  2018-11-19       Impact factor: 4.157

9.  Lower Levels of GABAergic Function Markers in Corticotropin-Releasing Hormone-Expressing Neurons in the sgACC of Human Subjects With Depression.

Authors:  Hyunjung Oh; Dwight Newton; David Lewis; Etienne Sibille
Journal:  Front Psychiatry       Date:  2022-02-25       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.